PCSK9 and peripheral arterial disease: Other parameters investigated were female sex (HR 1.5, 95% CI 0.9–2.4, p = 0.107), age ≥ 70 years (HR 1.3, 95% CI 0.8–2.2, p = 0.297), heterozygous or mixed dyslipidemia (HR 0.9, p = 0.732), coronary artery disease (HR 0.7, p = 0.255), cerebrovascular disease (HR 1.1, p = 0.839), peripheral artery disease (HR 1.2, p = 0.671),) office vs. hospital based initiation of therapy (HR 0.97, p = 0.904), and diabetes mellitus (HR 1.0, p = 0.878), but these were not statistically significantly associated with discontinuation of PCSK9-mAB (Fig. 2).